Reversal of multidrug resistance in drug-resistant cell line EAC/ADR by cepharanthine hydrochloride and its mechanism

Yaoxue Xuebao

Volumn 40, Issue 3, 2005, Pages 204-207

  Song, Yu Cheng ^a   Xia, Wei ^a   Jiang, Jin Hua ^a   Wang, Qing Duan ^a  

^a Henan Institute of Medical Sciences   (China)

Author keywords

Apoptosis; Cepharanthine hydrochloride; Ehrlich ascites carcinoma; Gene expression; Multidrug resistance; NF B

Indexed keywords

CEPHARANTHINE; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TETRAZOLIUM;

ALLOGRAFT; ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CELL LINE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; IN VITRO STUDY; LIFESPAN; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN FUNCTION; SURVIVAL TIME;

ALKALOIDS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, EHRLICH TUMOR; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; MALE; MICE; NEOPLASM TRANSPLANTATION; NF-KAPPA B; PLANT ROOTS; PLANTS, MEDICINAL; RANDOM ALLOCATION; STEPHANIA;

EID: 18244390938     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Pommier Y, Sordet O, Antony S, et al. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks [J]. Oncogene, 2004,23(16):2934-2949.
2. Arlt A, Schafer H. NFkappaB-dependent chemoresistance in solid tumors [J]. Int J Clin Pharmacol Ther, 2002,40(8):336-347.
3. Hotta T, Tanimura H, Yamaue H, et al. Modulation of multidrug resistance by cepharanthine in fresh human gastrointestinal tumor cells [J]. Oncology, 1997,54(2):153-157.
4. Okamoto M, Ono M, Baba M. Potent inhibition of HIV type 1 replication by an antiinflammatory alkaloid, cepharanthine, in chronically infected monocytic cells [J]. AIDS Res Hum Retroviruses, 1998,14(14):1239-1245.
5. Wang QD, Liu MJ, Li GD, et al. Establishment of multidrug resistance to adriamycin in Ehrlich ascites carcinoma in vivo [J]. Chin Pharmcol Bull, 1993,9(2):122-128.
6. Marks DC, Belov L, Davey MW, et al. The MTT cell viability assay for cytotoxicity testing in multidrug-resistant human leukemic cells [J]. Leuk Res, 1992,16(12):1165-1173.
7. Guo Y, Hu YF, Cheng GF. Induction of NF-κB in mouse peritoneal macrophages by inflammatory irritants [J]. Acta Pharm Sin, 1999,34(8):586-589.
8. Guo FK, Li YL, Wu SG. Detection of NF-κB by Sandwich ELISA [J]. Chin Pharmcol Bull, 2000,16(1):227-228.
9. Han R. Research and Development of Anticancer Drugs and Experimental Techniques [M]. Beijing: Peking Union Medical College and Beijing Medical University Press, 1997. 199-203.
10. Bharti AC, Aggarwal BB. Nuclear factor-kappa B and cancer: its role in prevention and therapy [J]. Biochem Pharmacol, 2002,64(5-6):883-888.
11. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB [J]. J Clin Invest, 2001,107(3):241-246.
12. Cui JQ. Summarize of pharmacological function of cepharanthine [J]. Chin Tradit Herb Drugs, 1995,26(9):502-503.